SEATTLE, Aug. 03, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Lexaria Bioscience Corp. (CSE:LXX) (LXX.CN) (CNSX:LXX) (OTCQX:LXRP). The company has spent the past several years focused on improving the bioavailability of cannabinoids, including CBD. Its DehydraTECH™ drug delivery platform has demonstrated significant improvements in bioavailability over conventional delivery methods — and its latest human clinical study confirmed these findings. Lexaria is now one of a very few select biotech companies to have completed a successful human clinical trial with cannabinoids.
The cannabidiol (CBD) market is projected to reach $2.1 billion by 2020, according to the Hemp Business Journal, which marks significant growth over last year’s roughly $200 million in revenue. Consumers and physicians are starting to realize the significant potential benefits of the cannabinoid in treating a wide range of disorders that can be tied back to the human endocannabinoid system and its far-reaching effects.
CBD Bioavailability Issues
There are many different cannabidiol (CBD) delivery methods available for consumers, patients, and physicians, including capsules, tinctures, vape oils, and even edibles, and each delivery method impacts the body in a different way. Most importantly, some delivery methods are associated with greater bioavailability — or the percentage of the compound that’s absorbed into the bloodstream after any other processing in the body.
Oral CBD supplements, such as capsules, edibles, and oils, must pass through the digestive system and circulate through the liver. These processes metabolize CBD and reduce the amount that ultimately reaches the bloodstream, thereby reducing the bioavailability. While there aren’t any studies about CBD bioavailability, there are some studies that have shown tetrahydrocannabinol (THC) bioavailability of between four and 20 percent for oral delivery.
Another common way to consume CBD is through inhalation using CBD vape oils. When a consumer vapes oil, CBD bypasses first-pass metabolism and enters the bloodstream through the lungs. THC studies have shown that this can enhance bioavailability to as much as 56 percent, although there is significant variance due to factors like how long the vapor is held in the lungs and the volume of inhalation for a given person.
Lexaria’s DehydraTECH™ drug delivery platform aims to improve bioavailability, as well as make the dosing more predictable across individuals.
By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the bitter and earthy taste of cannabis oil and ensures quick and effective transportation into the bloodstream without degradation in the stomach or liver (first pass metabolism). Early animal studies showed that this approach could significantly improve the bioavailability of cannabinoids.
On August 1, the company released the results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD™ — a proprietary DehydraTECH™ powered CBD hemp oil capsule. The study looked at the degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancements in 12 healthy male volunteers.
The study found that CBD absorption was more than three-times higher than the control at the 30 minute mark and continued to significantly surpass control blood level concentrations through the 360 minute measurements. Interestingly, the CBD absorption was even better than GW Pharmaceuticals’ (NASDAQ: GWPH) Mount Sinai study, which used much higher doses of 400mg and 800mg to achieve lower overall blood concentrations.
Lexaria Bioscience Corp.’s (OTCQX: LXRP) (CSE: LXX) DehydraTECH™ has consistently demonstrated superior bioavailability versus other products on the market. In addition to CBD, the company has been actively researching the drug delivery platform’s potential in improving the bioavailability of other cannabinoids and other drugs. It has over 40 patents pending and 8 patents granted around the world protecting these innovations, yielding significant licensing opportunities down the road.
For more information, visit the company’s website at www.lexariabiosciences.com.
Please follow the link to read the full article: http://www.cannabisfn.com/lexarias-dehydratech-triples-bioavailability-cbd-human-trial/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/